Vaccines Market Research

Vaccines Market Research Reports & Industry Analysis

10 January 2020
Pharma
Vaccines Market Research

The global vaccine market is a steady grower, while also providing an absolutely vital medical service to billions of people around the world.  This makes the vaccines market a strong candidate for investment, as long as a company understands the risks involved.  This is what Visiongain specializes in.  We do in-depth vaccine market research, along with many other industries, to bring you the information needed to make strong decisions.

Our reports touch on many areas of the topic; here is a brief summary of the current state of the vaccine market research.

Vaccines Overview

Vaccines specifically formulated substances that improve human immunity to a variety of diseases.  Each vaccine is tailored to a specific disease, usually utilizing a dead or dormant form of that disease to train the body's immune system to fight it.  Currently, the primary market segmentations are for live attenuated vaccines, inactivated vaccines, and subunit/recombinant vaccines. 

Vaccines Market Global Outlook

On the whole, the vaccine market shows a growth rate of approximately 6.67% and is forecasted to remain there until the mid-2020s.   Of the various market segments, live attenuated vaccines (which use live, but harmless, disease matter) is by far the most dominant, accounting for the majority of vaccines in use.  The growth in this segment is projected to have a CAGR of 5.44% in the near future.

Of vaccines currently on the market, one strong growth area is in vaccines for the Human Papilloma Virus.  HPV is a mild sexually transmitted disease which is also linked to cervical cancer, and its vaccine being increasingly mandated by world governments.

As such, growth in the vaccine market is seen as largely government-driven.  States implement initiatives mandating vaccination, causing immediate boosts to the industry.  This fuels research into new vaccines, which are then introduced to the market.

Major Challenges to The Global Vaccine Market

Expansion into developing nations has been a continual challenge.  Many governments are at times disinterested in public health initiatives, or else lack the resources to implement widespread vaccination.  There is also a substantial lack of education among the public and some lingering distrust of vaccines themselves. These issues create uncertainty in the ability of the market to grow globally.

In addition, the production of new vaccines is extremely expensive, with long and arduous regulations that must be cleared, slowing the introduction of new products.

Visiongain has far more insights to share.  Click here to browse our selection of pharmaceutical market research.

Recent News

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

Read

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever